Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0SDZSF
ADC Name	Lorvotuzumab mertansine
Synonyms	BB-10901; huN-901-DM1; huN-901-SPP-DM1; huN901-DM1; huN901-SPP-DM1; IMGN-901; IMGN-901-TAP; IMGN901 TAP; huN901-DM1 antibody; Monoclonal antibody huN901-DM1 conjugate Click to Show/Hide
Organization	ImmunoGen, Inc.
Drug Status	Phase 2
Indication	In total 5 Indication(s) Small cell lung cancer [ICD11:2C25] Phase 2 Merkel cell carcinoma [ICD11:2C34] Terminated in phase 2 Multiple myeloma [ICD11:2A83] Terminated in phase 2 Ovarian cancer [ICD11:2C73] Terminated in phase 2 Small cell carcinoma [ICD11:XH0YB0] Terminated in phase 2
Drug-to-Antibody Ratio	3-4
Structure
	3D MOL	2D MOL
Antibody Name	Lorvotuzumab		Antibody Info
Antigen Name	Neural cell adhesion molecule 1 (NCAM1)		Antigen Info
Payload Name	Mertansine DM1		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	N-succinimidyl 4-(2-pyridyldithio) pentanoate (SPP)		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.
Combination Type	Mertansine
Puchem SID	472423463 , 135334551 , 347911280 , 124490621 , 160687958 , 440801302 , 178104003 , 385788099
Drugbank ID	DB12089
ChEBI ID	CHEMBL1743037

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT00346255	Phase 1	BB-10901 in treating patients with relapsed and/or refractory multiple myeloma (IMGN901).

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	28.30%	Positive CD56 expression (CD56+++/++)
Patients Enrolled	Relapsed and/or Refractory CD-56-positive Multiple Myeloma.
Administration Dosage	40 mg/m² (up to a maximum of 140 mg) intravenously once every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT00346255	Clinical Status	Phase 1
Clinical Description	BB-10901 in treating patients with relapsed and/or refractory multiple myeloma (IMGN901).
Primary Endpoint	Objective response rate=28.30%.
Other Endpoint	Median progression-free survival=26.10 months (95% CI 1-89 weeks).

References

Ref 1	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34. doi: 10.1016/j.clml.2018.08.018. Epub 2018 Sep 5.